Posted by ABMN Staff on Apr 26th, 2024
Quest Diagnostics (NYSE:DGX – Get Free Report) had its price objective upped by investment analysts at UBS Group from $139.00 to $146.00 in a research note issued to investors on Wednesday, Benzinga reports. The firm presently...
More of this article »